Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
brentuximab vedotin + rifampicin
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
Brentuximab vedotin is an antibody-drug conjugate composed of a chimeric IgG1 antibody directed against CD30, covalently linked to the microtubule-disrupting agent monomethyl auristatin E (MMAE). It binds to CD30-expressing cells, is internalized, and releases MMAE intracellularly via proteolytic cleavage. This disrupts the microtubule network, causing cell cycle arrest and apoptosis in malignant cells. Brentuximab vedotin is primarily indicated for various types of lymphoma including classical Hodgkin lymphoma (cHL), systemic anaplastic large cell lymphoma (sALCL), primary cutaneous anaplastic large cell lymphoma, and CD30-expressing mycosis fungoides[1][2][3][4][5]. Rifampicin is a small molecule antibiotic that inhibits bacterial DNA-dependent RNA polymerase. It is used mainly for the treatment of tuberculosis and other mycobacterial infections.
- Brand names
- AdcetrisRifadinRimactane
- Other names
- none
02
Targets
TUBB (Tubulin (alpha and beta subunits))CD30 (CD30 antigen)RNAP (Bacterial dna-dependent RNA polymerase)
Beyond the preview
Go deeper on brentuximab vedotin + rifampicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on brentuximab vedotin + rifampicin.